A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours

Biotheus Inc.30 enrolled

Overview

The purpose of this research is to assess the safety, tolerability and effectiveness of PM1021 Monotherapy and PM1021 in Combination with PM8001 in Patients with Advanced Solid Tumours. In this study, up to 30 patients will be enrolled in Australia only. Advanced solid cancers are associated with poor prognosis and pose a significant challenge for treatment strategies. Effective treatments for advanced metastatic malignancies that have failed available standard of care treatment represent a major unmet medical need. Biotheus Inc. is developing PM1021, a monoclonal anti-T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibody (IgG1) and PM8001 (a PD-L1/TGF-beta bispecific Fc fusion protein) as treatment for advanced solid tumours.

This is a single-arm, open-label, Phase I study including a first-in-human study for PM1021, and the combination therapy of PM1021 with PM8001. The study will be following the accelerated titration design and the classic 3+3 design, and dose escalation will be investigated for PM1021 monotherapy (Part A) and in combination with PM8001 (Part B), respectively. In the absence of DLTs in Parts A and B, patients will continue to receive combination therapy (Part C) until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion. Up to 30 patients are planned to be enrolled. Four dose levels (150mg, 450 mg, 900 mg, and 1200 mg) of PM1021 with or without PM8001 (20 mg/kg) treatment will be explored in this study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, aged 18-75 years (inclusive) on the day of signing the consent form; * Patients with histologically or cytologically confirmed advanced solid tumours; * Evidence of adequate organ function; * Eastern Cooperative Oncology Group score is 0-1; * Expected survival greater than or equal to 12 weeks in the opinion of the Investigator; * Female patients must: 1. Be of non-child-bearing potential i.e. surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the Screening visit) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone level consistent with postmenopausal status, per local laboratory guidelines), or 2. If of child-bearing potential, must agree not to attempt to become pregnant, must not donate ova, and, if engaging in sexual intercourse with a male partner, must agree to use an acceptable method(s) of contraception from signing the consent form until at least 5 months after the last dose of study drug; * Male patients must agree not to donate sperm and if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception from signing the consent form until at least 5 months after the last dose of study drug; Exclusion Criteria: * History of serious allergic diseases, history of serious drug allergy or known allergy to any component of the drugs in this study; * Clinically significant active infection within 2 weeks prior to the start of study treatment; * Previously received treatment with PD-L1 or TIGIT monoclonal/bispecific antibody, or targeting TGF-β drugs; * Previously received immunotherapy and have experienced ≥ Grade 3 immunotherapy-related adverse events or ≥ Grade 2 immune-related myocarditis; * The adverse reactions of previous anti-tumour treatment have not recovered to NCI-CTCAE V5.0 Grade ≤ 1; * Patients who have received the following therapies or drugs prior to the start of study treatment: 1. Patients who have undergone major organ surgery within 28 days prior to the start of study treatment; 2. Patients who have been vaccinated with live or live-attenuated vaccine within 28 days prior to the start of study treatment; 3. Patients who have received chemotherapy, radical/extensive radiotherapy, endocrine therapy and other anti-tumour drug therapies within 4 weeks prior to the start of study treatment; 4. Patients who have received systemic glucocorticoids (prednisone \>10 mg/day or equivalent dose of similar drugs) or other immunosuppressive therapies within 14 days prior to the start of study treatment; * Patients with known meningeal metastases or uncontrollable central nervous system metastases, manifested as cerebral edema, spinal cord compression and/or progressive growth; * Patients with active or previous autoimmune diseases with possible recurrence, except for clinically stable patients with autoimmune thyroid disease and type I diabetes; * Patients who have had other active malignant tumours within 5 years prior to the start of study treatment, except for those which can be treated locally and have been cured; * Patients with a history of serious cardio-cerebrovascular diseases; * Presence of poorly controlled diabetes prior to the start of study treatment; * Current presence of uncontrollable pleural, pericardial and peritoneal effusions; * History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; * Patients unlikely to comply with the clinical study protocol; * Known substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the patient's participation in the clinical study or evaluation of the clinical study results; * History of immunodeficiency, including a positive HIV antibody test; * Active hepatitis B, hepatitis C, or syphilis infection; * Patients with a positive coronavirus (COVID-19) nucleic acid test at screening; * Women who are pregnant or breastfeeding; * Other conditions deemed by the Investigator to be inappropriate for participation in this study.

Outcomes

Primary Outcomes

DLT

The incidence of DLTs in PM1021 monotherapy and PM1021 combination therapy with PM8001, respectively.

Time frame: Part A: up to 21 days. Part B: up to 21 days.

AEs and SAEs

The incidence and severity of treatment-emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) graded according to NCI-CTCAE v5.0.